Versant Venture Management, LLC - CYMABAY THERAPEUTICS INC ownership

CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 102 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.4%.

Quarter-by-quarter ownership
Versant Venture Management, LLC ownership history of CYMABAY THERAPEUTICS INC
ValueSharesWeighting
Q2 2023$5,954,095
+25.6%
543,7530.0%7.06%
-28.5%
Q1 2023$4,741,526
+39.1%
543,7530.0%9.88%
+40.1%
Q4 2022$3,409,330
+79.2%
543,7530.0%7.06%
+117.5%
Q3 2022$1,903,000
+18.6%
543,7530.0%3.24%
+31.9%
Q2 2022$1,604,000
-5.1%
543,7530.0%2.46%
+45.7%
Q1 2022$1,691,000
-8.0%
543,7530.0%1.69%
+71.7%
Q4 2021$1,838,000
-7.4%
543,7530.0%0.98%
+19.6%
Q3 2021$1,985,000
-16.3%
543,7530.0%0.82%
+4.6%
Q2 2021$2,371,000
-4.0%
543,7530.0%0.79%
+63.4%
Q1 2021$2,469,000
-20.9%
543,7530.0%0.48%
+48.5%
Q4 2020$3,121,000
-20.7%
543,7530.0%0.32%
-55.1%
Q3 2020$3,937,000
-99.8%
543,7530.0%0.72%
+164.1%
Q2 2020$1,897,697,000
+135.8%
543,7530.0%0.27%
+23.5%
Q1 2020$804,754,000
-24.5%
543,7530.0%0.22%
-31.2%
Q4 2019$1,065,755,000
-61.7%
543,7530.0%0.32%
-70.2%
Q3 2019$2,784,014,000
-28.5%
543,7530.0%1.08%
-5.0%
Q2 2019$3,893,270,000
-73.0%
543,753
-49.9%
1.13%
-76.2%
Q1 2019$14,442,063,000
+69.2%
1,084,6960.0%4.76%
+12.6%
Q4 2018$8,536,555,000
-29.0%
1,084,6960.0%4.23%
+3.4%
Q3 2018$12,018,432,000
-14.6%
1,084,696
+3.4%
4.09%
-6.9%
Q2 2018$14,072,225,000
+3.3%
1,048,6010.0%4.39%
+0.8%
Q1 2018$13,621,327,000
+41.2%
1,048,6010.0%4.36%
-57.1%
Q4 2017$9,647,127,000
+16.8%
1,048,6010.0%10.15%
+61.4%
Q3 2017$8,262,974,000
+36.8%
1,048,6010.0%6.29%
+32.4%
Q2 2017$6,039,940,000
+34.0%
1,048,6010.0%4.75%
+44.9%
Q1 2017$4,508,983,000
+148.6%
1,048,6010.0%3.28%
+85.7%
Q4 2016$1,814,080,000
-10.8%
1,048,6010.0%1.77%
-22.1%
Q3 2016$2,034,286,000
+11.5%
1,048,6010.0%2.27%
+22.7%
Q2 2016$1,824,566,000
+28.9%
1,048,6010.0%1.85%
+80.9%
Q1 2016$1,415,611,000
-20.1%
1,048,6010.0%1.02%
-1.4%
Q4 2015$1,772,135,000
-12.9%
1,048,6010.0%1.04%
-11.1%
Q3 2015$2,034,285,000
-27.9%
1,048,6010.0%1.17%
-67.4%
Q2 2015$2,820,736,000
-61.1%
1,048,6010.0%3.58%
-43.9%
Q1 2015$7,256,319,000
-29.6%
1,048,6010.0%6.38%
-35.2%
Q4 2014$10,307,748,0001,048,6019.86%
Other shareholders
CYMABAY THERAPEUTICS INC shareholders Q3 2022
NameSharesValueWeighting ↓
Foresite Capital Management III, LLC 1,641,804$7,454,0006.54%
COMMODORE CAPITAL LP 2,983,513$13,545,0005.40%
Foresite Capital Management IV, LLC 1,787,094$8,113,0000.97%
Avoro Capital Advisors LLC 10,300,000$46,762,0000.81%
Boxer Capital, LLC 4,000,000$18,160,0000.62%
Sio Capital Management, LLC 562,339$2,553,0000.52%
ACUTA CAPITAL PARTNERS, LLC 315,341$1,432,0000.52%
CM Management, LLC 150,000$681,0000.51%
APIS CAPITAL ADVISORS, LLC 120,000$545,0000.50%
Versant Venture Management, LLC 543,753$2,469,0000.48%
View complete list of CYMABAY THERAPEUTICS INC shareholders